An Overview on COVID-19 and its Effect on Cardiovascular Diseases

(E-pub Ahead of Print)

Author(s): Abdullah Hamadi*, Ali Mahzari, Abdulrahim Hakami, Salwa Hindawi, Gasim Dobie, M. I Sayyed, Fawaz Hamdi, Mohammed Nahari, Denise E. Jackson

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders


Become EABM
Become Reviewer
Call for Editor

Abstract:

COVID-19 (Virus named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) is a pandemic disease characterized with respiratory infection caused by coronavirus. It has worldwide after an outbreak began in Wuhan, China, in December 2019. SARS-CoV-2 has infected more than 15 million people globally. The disease severity and mortality increased in patients with heart-related comorbidities. Cardiovascular disease patients are more susceptible and infected with SARS-CoV-2. Early screening and managements these patients prevent or ameliorate adverse outcomes. Several treatments have been used to combat these effects as previously seen in MERS and SARS. This review will cover the association of cardiovascular diseases with COVID 19. It showed that cardiovascular diseases are common in patients with COVID- 19. Increased attention to highlight the gaps should be paid to the care of this unique group of patients.

Keywords: COVID-19, SARS-CoV-2, cardiovascular, treatment, heart disease, hypertension.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871530321999201228214718
Price: $95

Article Metrics

PDF: 173